Summary

Fermenta Biotech Limited reported a consolidated revenue of INR 547.8 crore for FY26, representing a 14% year-over-year increase. The company's consolidated EBITDA, excluding real estate, saw a substantial rise of 44% to INR 120 crore, primarily fueled by robust growth in its Vitamin D3 - Human Nutrition segment. While Profit after Tax for FY26 decreased by 8% to INR 70.3 crore, this decline was largely due to a higher base in FY25 from one-time real estate value-unlocking inflows. Management highlighted that the strong FY26 performance confirms the turnaround from FY25 and positions the company for continued value creation.

Key Highlights

1. 1

   Consolidated revenue for FY26, including real estate, reached INR 547.8 crore, marking a 14% increase year-over-year.

2. 2

   Consolidated EBITDA for FY26, excluding real estate, significantly grew by 44% year-over-year to INR 120 crore, primarily driven by strong performance in Vitamin D3 - Human Nutrition.

3. 3

   Profit after Tax for FY26 stood at INR 70.3 crore, an 8% decrease year-over-year, attributed to a high FY25 base from one-time real estate value-unlocking inflows of INR 44.6 crore.

4. 4

   Revenue from the Vitamin D3 – Human Nutrition segment increased by 28% to INR 292.7 crore in FY26, highlighting robust performance in a key business area.

5. 5

   Green Chemistry sales more than doubled over FY25, benefiting from the acquisition of new customers, reflecting successful business development.

6. 6

   The German toll manufacturing subsidiary's FY26 revenue increased by 101% year-over-year to INR 76.6 crore, indicating significant international growth.

7. 7

   Adjusted for one-off real estate value-unlocking income, underlying Profit After Tax in FY26 was materially higher than FY25, consistent with the 44% YoY EBITDA growth.